Sam Brusco, Associate Editor03.18.24
Intuitive has gained U.S. Food and Drug Administration (FDA) 510(k) clearance for da Vinci 5, its next-generation multiport robotic surgical system.
Da Vinci 5’s design and engineering enhancements include new surgeon controllers and vibration/tremor controls. It’s equipped with the company’s most natural 3D imaging system, as well.
The surgical robot’s new Force Feedback technology and instruments let the system measure, and surgeons feel, subtle forces exerted on tissue during surgery. The company said in preclinical trials Force Feedback showed up to 43% less force exerted on tissue. Its instruments are cleared for use in the same procedures as da Vinci XI, save for cardiac and pediatric, and have a specific contraindication for using the needle driver during suturing in hysterectomy and myomectomy surgeries.
da Vinci 5 has integrated insufflation and an electrosurgical unit. An optimized user interface has settings accessible by the broader surgical team and by the surgeon directly from the head-in menu.
Intuitive also said da Vinci 5 has over 10,000 times the computing power of da Vinci Xi. It enables capabilities like integration with the My Intuitive app, SimNow virtual reality simulator, Case Insights computational observer, and the Intuitive Hub edge computing system.
A redesigned console allows customizable positioning for surgical viewing and comfort. Adjustments can be made while the surgeon’s head is in the console, with options for fitting different body types, including surgeons who are pregnant.
Da Vinci 5 will first be available to a small number of U.S. customers who collaborated with Intuitive during the development phase, as well as those with mature robotic surgery programs, the company said.
“We design our systems so we can integrate new functions, capabilities, indications, and instrumentation over time,” said Intuitive’s chief medical officer Myriam Curet, MD. “Our careful attention to customers’ long-term needs and goals has led our systems to become the hospital standard, and we expect to continue developing and innovating da Vinci 5 and da Vinci Xi over the coming years.”
“We are pleased to receive FDA clearance for our fifth-generation robotic system, da Vinci 5,” said Intuitive CEO Gary Guthart. “Intuitive is committed to meaningful improvements in surgery that enable better patient outcomes, enhance the patient and care team experiences, and ultimately lower the total cost of care. After more than a decade of careful research, design, development, and testing, we believe da Vinci 5 will deliver on these goals and help drive the future of robotic-assisted surgery.”
Da Vinci 5’s design and engineering enhancements include new surgeon controllers and vibration/tremor controls. It’s equipped with the company’s most natural 3D imaging system, as well.
The surgical robot’s new Force Feedback technology and instruments let the system measure, and surgeons feel, subtle forces exerted on tissue during surgery. The company said in preclinical trials Force Feedback showed up to 43% less force exerted on tissue. Its instruments are cleared for use in the same procedures as da Vinci XI, save for cardiac and pediatric, and have a specific contraindication for using the needle driver during suturing in hysterectomy and myomectomy surgeries.
da Vinci 5 has integrated insufflation and an electrosurgical unit. An optimized user interface has settings accessible by the broader surgical team and by the surgeon directly from the head-in menu.
Intuitive also said da Vinci 5 has over 10,000 times the computing power of da Vinci Xi. It enables capabilities like integration with the My Intuitive app, SimNow virtual reality simulator, Case Insights computational observer, and the Intuitive Hub edge computing system.
A redesigned console allows customizable positioning for surgical viewing and comfort. Adjustments can be made while the surgeon’s head is in the console, with options for fitting different body types, including surgeons who are pregnant.
Da Vinci 5 will first be available to a small number of U.S. customers who collaborated with Intuitive during the development phase, as well as those with mature robotic surgery programs, the company said.
“We design our systems so we can integrate new functions, capabilities, indications, and instrumentation over time,” said Intuitive’s chief medical officer Myriam Curet, MD. “Our careful attention to customers’ long-term needs and goals has led our systems to become the hospital standard, and we expect to continue developing and innovating da Vinci 5 and da Vinci Xi over the coming years.”
“We are pleased to receive FDA clearance for our fifth-generation robotic system, da Vinci 5,” said Intuitive CEO Gary Guthart. “Intuitive is committed to meaningful improvements in surgery that enable better patient outcomes, enhance the patient and care team experiences, and ultimately lower the total cost of care. After more than a decade of careful research, design, development, and testing, we believe da Vinci 5 will deliver on these goals and help drive the future of robotic-assisted surgery.”